FIGURE 5 Discussion This study, based on real-world data from the FAERS database, comprehensively evaluated the post-marketing safety of HCQ and chloroquine CQ in the treatment of SLE, providing updated insights into ocular adverse events associated with these agents
The recommended injection sites for GLP-1 medications include the abdomen (at least 2 inches from the navel), the front of the thigh, and the back of the upper arm
The findings appeared on July 22, 2025 in BMJ Open Diabetes Research & Care Given the severe societal, familial, and economic burden of diabetes-related dementia, these findings raise important considerations about the role of GLP-1 [receptor agonists] as first-line therapies in [type 2 diabetes] management, the authors said
A 2023 analysis in The Lancet of GLP-1 agonist discontinuation found that patients who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within one year [19]
In one study, integrating ePA into the prescribing workflow yielded over 80% faster turnaround times and 10-hour faster submission turnaround on average ( [7] )
Accelerated weight gain, prematurity, and the risk of childhood obesity: A meta-analysis and systematic review